SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (5550)1/25/2002 9:58:44 AM
From: seminole  Read Replies (1) | Respond to of 52153
 
A large number of shareholders expected a Euro partner last year.
However, the stock offering in Oct. can be taken as a signal that they are in no hurry to sign with a partner.

I don't believe they ever will give up the U.S. rights to the drug and
my guess is that they are looking for product instead of cash for the Euro rights to IRO.



To: Miljenko Zuanic who wrote (5550)4/17/2002 7:04:36 PM
From: Miljenko Zuanic  Respond to of 52153
 
Message 16958343

Have no pleasure in Irofulven failure, but record is record.
And, it is going way back to 1997.

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News